The panellists voted about several questions regarding recommendations for adjuvant chemotherapy in patients with triple-negative breast cancer. All panellists agreed that for patients with pT1a, pN0 (tumour <6 mm), triple-negative breast cancer, chemotherapy is not always indicated; 35% of the panellists took the view that chemotherapy for these patients is never indicated, 65% of the panellists were of the opinion that chemotherapy for these patients is sometimes indicated. In general, the preferred chemotherapy regimen for patients with stage 1 triple-negative breast cancer should contain anthracyclines, alkylators, and taxanes, according to 78% of the panellists, while 50% of the panellists preferred chemotherapy with only alkylators and taxanes in case a stage 1 triple-negative breast cancer patient has a tumour with a size ≤1 cm. For patients with stage 2 triple-negative breast cancer, almost all panellists (94%) were in favour of a chemotherapy regimen containing anthracycline, alkylator, and taxane.
« Minimally invasive surgical techniques must compete against pharmacotherapy in benign prostate hyperplasia (BPH) Next Article
Penile prosthesis implantation »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.